Bullish Or Bearish For Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) In 2023

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares, rose in value on Thursday, 06/15/23, with the stock price up by 1.04% to the previous day’s close as strong demand from buyers drove the stock to $0.08.

Actively observing the price movement in the last trading, the stock closed the session at $0.08, falling within a range of $0.0742 and $0.079. The value of beta (5-year monthly) was 2.12. Referring to stock’s 52-week performance, its high was $20.80, and the low was $0.07. On the whole, BDRX has fluctuated by -65.68% over the past month.

Top 5 AI Stocks to Buy for 2023

The artificial intelligence (AI) revolution is already here. And it’s about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.

Click Here to Download the FREE Report.


Analysts have estimated the company’s revenue for the quarter at $240k, with a low estimate of $240k and a high estimate of $240k.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that BDRX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

1 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 0 recommend it as a Buy and 0 called the BDRX stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Hold.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of BDRX currently trading nearly -36.37% and -60.95% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 21.99, while the 7-day volatility ratio is showing 7.20% which for the 30-day chart, stands at 10.61%. Furthermore, Biodexa Pharmaceuticals Plc (BDRX)’s beta value is 2.13, and its average true range (ATR) is 0.02. The company’s stock has been forecasted to trade at an average price of $3149.49 over the course of the next 52 weeks, with a low of $3149.49 and a high of $3149.49. Based on these price targets, the low is -3936762.5% off current price, whereas the price has to move -3936762.5% to reach the yearly target high. Additionally, analysts’ median price of $3149.49 is likely to be welcomed by investors because it represents a decrease of -3936762.5% from the current levels.

Data on historical trading for Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) indicates that the trading volumes over the past 10 days have averaged 3.91 million and over the past 3 months, they’ve averaged 3.71 million. According to company’s latest data on outstanding shares, there are 41.47 million shares outstanding.

Biodexa Pharmaceuticals Plc’s shares belong to company insiders and institutional investors own 5.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.11 million shares as on May 30, 2023, resulting in a short ratio of 0.04. According to the data, the short interest in Biodexa Pharmaceuticals Plc (BDRX) stood at 0.59% of shares outstanding as of May 30, 2023; the number of short shares registered in Apr 27, 2023 reached 0.18 million. The stock has fallen by -98.03% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BDRX stock heading into the next quarter.